Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC

BIN-CHI LIAOCHIH-HSIN YANG2021-09-142021-09-142021-09-0115560864https://scholars.lib.ntu.edu.tw/handle/123456789/582855[SDGs]SDG3Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLCother10.1016/j.jtho.2021.06.0282-s2.0-85113798020https://api.elsevier.com/content/abstract/scopus_id/85113798020